BioProgress files patent for film system technology
UK-based BioProgress Technology, a subsidiary of speciality pharma and healthcare company BioProgress plc, has filed a UK patent application for the use of its XGEL film system technology in a waste containment system to help prevent the spread of MRSA (Methicillin Resistant Staphylococcus Aureus) in hospitals.
The development of the containment system was assisted by the company’s Advisory Board, which has also been involved with making recommendations for MRSA prevention systems for use across the UK’s National Health Service. BioProgress will explore whether there are additional areas in which the containment system or the XGEL film technology could be of use within the medical device sector.
BioProgress is continuing to expand its patent families by filing applications in numerous international territories which claim priority from existing applications filed in the UK or through the Patent Co-operation Treaty route. At present, the group owns 40 granted patents in 31 different patent families.
“The company continues to apply for patents to protect relevant commercial applications of its novel XGEL systems, said Richard Trevillion, ceo. “With respect to the MRSA prevention system, this is an endorsement of our market-led approach and illustrates how the non-ingestible containment side of our business can have real commercial advantages.
“We believe the system to be simple, not adding further complexity to the operating theatre, and helping to reduce the risk of infection.”